Chief Financial Officer · LIGAND PHARMACEUTICALS INC (LGND)

Octavio Espinoza

A named executive officer of LIGAND PHARMACEUTICALS in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$4,382,148

FY2024: $3,298,556

Compensation figures as of the proxy filed April 21, 2026 (DEF 14A).

Octavio Espinoza compensation by year

LIGAND PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as LIGAND PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$433,005$469,550$522,825
Bonus$0$0$0
Stock awards$1,201,271$1,428,806$1,932,219
Option awards$635,773$1,142,820$1,554,411
Non-equity incentive$173,202$250,000$357,750
Pension and deferred compensation$0$0$0
All other$7,380$7,380$14,943
Total$2,450,631$3,298,556$4,382,148

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LIGAND PHARMACEUTICALS INC DEF 14A filed April 21, 2026, accession 0000886163-26-000021, and prior-year filings. Open the filing on EDGAR.

$2.5M
$3.3M
$4.4M
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

LIGAND PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Todd DavisChief Executive Officer$11,472,095
Octavio Espinoza · this pageChief Financial Officer$4,382,148
Andrew ReardonChief Legal Officer and Secretary$3,747,282

The full LIGAND PHARMACEUTICALS compensation record

free company brief

This page is one person within LIGAND PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order LIGAND PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LIGAND PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy